Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Good viruses vs. bad bacteria: new treatment tested for CF lungs

NCT ID NCT07275905

Summary

This early-stage study is testing whether a new treatment called AchromoPhage is safe for adults with cystic fibrosis who have long-term lung infections. AchromoPhage is a mix of four natural viruses designed to find and kill a specific type of bacteria in the lungs. The study will enroll 12 people to try the treatment in different ways—inhaled, given through a vein, or both—to see how their bodies react over six weeks.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of California San Diego (UCSD)

    San Diego, California, 92037, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Pittsburgh

    Pittsburgh, Pennsylvania, 15213, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.